ABCA1 유전자의 새로운 돌연변이로 인한 Tangier병

박형기 ( Hyung Ki Park ),서승오 ( Seong O Suh ),안석진 ( Seok Jin Ahn ),정준오 ( Jun Oh Jung ),박상준 ( Sang Jun Park ),김희진 ( Hee Jin Kim ),박형두 ( Hyung Doo Park ) 대한내과학회 2010 대한내과학회지 Vol.78 No.2

Tangier disease (TD) is a rare autosomal recessive disorder of lipoprotein metabolism characterized by extremely low levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (apo) A-I resulting in accumulation of cholesterol esters in various organs. TD is caused by mutations in the ATP-binding cassette transporter A1 (ABCA1) gene. Here, we present the first case report of a Korean patient with TD. A 45-year-old man had corneal opacity, intestinal mucosa abnormalities, and extremely low levels of HDL-C (1.8mg/dL) and apo A-I (<10mg/dL), consistent with a diagnosis of TD. Histologically, foamy macrophages were recognized in the submucosa of the duodenum and colon. We performed PCR-sequencing for all ABCA1 coding exons to confirm genetic abnormalities. Two novel mutations in the ABCA1 gene were identified: i.e., c.3148G>T (p.G1050X) nonsense mutation and c.3202C>T (p.R1068C) missense mutation. The c.3202C>T mutation was not found in 192 normal control alleles. (Korean J Med 78:241-246, 2010)

A Correlation Analysis of Serum Creatinine Based eGFR and Serum Cystatin C Based eGFR with Thyroid Dysfunction Patients

임구,박형두,성호중,Lim, Gu,Park, Hyung-Doo,Sung, Ho Joong Korean Society for Clinical Laboratory Science 2017 대한임상검사과학회지(KJCLS) Vol.49 No.3

Serum creatinine-based eGFR and serum cystatin C-based eGFR are the most popular methods for measuring renal function. Thyroid hormone is known to affect serum creatinine-based eGFR and serum cystatin C-based eGFR; however, the clinical significance of thyroid dysfunctional patients of renal function evaluation has not been fully elucidated to date. This study examined the effect of thyroid hormone on serum creatinine-based eGFR and serum cystatin C-based eGFR. Moreover, we also evaluated the correlation analysis between serum creatinine-based eGFR and serum cystatin C-based eGFR in patients with thyroid dysfunction. A total of 442 patients with hypothyroidism and 284 patients with hyperthyroidism were investigated. A correlation analysis between thyroid hormone and serum creatinine- (and cystatin C-) based eGFR was performed. A correlation analysis between thyroid hormone and serum cystatin-C based eGFR indicated that serum cystatin-C based eGFR is more of an independent biomarker than serum creatinine-based eGFR in thyroid dysfunction patients. Therefore, serum cystatin C-based eGFR more accurately reflects renal function than serum creatinine-based eGFR in thyroid dysfunction patients.

Neonatal Onset Isovaleric Acidemia with Novel Mutation

김영한,배은주,박형두,이홍진,Kim, Young Han,Bae, Eun Ju,Park, Hyung-Doo,Lee, Hong Jin The Korean Society of Inherited Metabolic Disease 2016 대한유전성대사질환학회지 Vol.16 No.1

Isovaleric acidemia is autosomal-recessively inherited and an inborn error of metabolism caused by abnormal leucine metabolism due to the genetic defect of IVD (Isovaleryl-CoA dehydrogenase). IVD corresponds to mitochondrial matrix enzyme that acts on converting isovaleryl-CoA into 3-methylcrotonyl-CoA in the leucine catabolism. The IVD gene is located at Chromosome 15q14-q15, particularly between base pair 40,405,485 and base pair 40,435,948. It consists of 12 exons and has been reported to cause over 50 diseases so far. We conducted IVD gene test on the patient with acute isovaleric acidemia and confirmed a new type of mutation for the first time. As a result of analyzing the IVD gene sequence, we found out that c.129T>G(p.Asn43Lys) and c.1033A>G(p.Asn345Asp) mutations exist as heterozygosity at Exon 1 and Exon 10 respectively, novel mutation.

생화학적 검사 및 분자유전학적 검사에 의해 뮤코다당증 제3A형으로 진단된 한국인 환자의 증례 보고

김보람,조성윤,손영배,박형두,이수연,송정한,진동규,Kim, Borahm,Cho, Sung Yoon,Sohn, Young Bae,Park, Hyung-Doo,Lee, Soo-Youn,Song, Junghan,Jin, Dong-Kyu 대한유전성대사질환학회 2015 대한유전성대사질환학회지 Vol.15 No.1

뮤코다당증 제3A형(Mucopolysaccharidosis IIIA, Sanfillippo syndrome type A)은 heparan sulfate 대사에 관여하는 heparan N-sulfatase의 결핍으로 유발되는 리소좀 축적 질환이다. 본 연구는 대두증과 발달 지연을 보이는 5세 환아를 대상으로 하였다. 환아 소변의 glycosaminoglycan은 26 g/moL creatinine으로 증가되어 있었고(참고치: <7 g/moL creatinine), 소변의 전기영동 검사에서는 heparan sulfate 분획이 뚜렷하게 관찰되었다. 피부 섬유아세포에서 측정한 heparan N-sulfatase 활성도는 0.2 pmol/min/mg protein으로 매우 감소되어 있었다(참고치: 9-64 pmol/min/mg protein). 중합효소연쇄반응-염기서열분석법에 의한 SGSH 유전자 검사에서는 c.1040C>T (p.S347F) 및 c.703G>A (p.D235N) 돌연변이가 각각 이형접합체 양상으로 나타났다. 이에 생화학적 검사 및 분자유전학적 검사를 통해 뮤코다당증 제3A형으로 확진된 첫 번째 한국인 사례를 보고하는 바이다. Mucopolysaccharidosis (MPS) IIIA is a lysosomal storage disorder caused by abnormalities of the enzyme Heparan N-sulfatase that is required for degradation of heparan sulfate. The patient in this study was a 5 year-old boy who presented with macrocephaly and developmental delay. Urinary excretion of glycosaminoglycan was increased (26 g/moL creatinine, reference range: <7 g/moL creatinine) and a distinct band of heparan sulfate was shown in electrophoresis. Heparan N-sulfatase activity was significantly decreased in skin fibroblasts (0.2 pmoL/min/mg protein, reference range: 9-64 pmoL/min/mg protein). PCR and direct sequencing analysis of the SGSH gene showed compound heterozygous mutations: c.1040C>T (p.S347F) and c.703G>A (p.D235N). This is the first report for a Korean patient with MPS IIIA who was confirmed by biochemical investigation and molecular genetic analyses.

신생아기에 새로운 CPS1 유전자 돌연변이가 확인되고, 간세포이식 시행 받은 Carbamoyl phosphatase synthetase 1 deficiency 1례

이지선,양아람,김진섭,박형두,이상훈,이석구,조성윤,진동규,Lee, Jisun,Yang, Aram,Kim, Jinsup,Park, Hyung-Doo,Lee, Sanghoon,Lee, Suk-Koo,Cho, Sung Yoon,Jin, Dong-Kyu 대한유전성대사질환학회 2017 대한유전성대사질환학회지 Vol.17 No.1

Carbamoyl phosphate synthetase 1 (CPS1) 결핍은 요소회로 이상 질환 중 하나로 상염색체 열성으로 유전되며 2q35 염색체에 존재하는 CPS1 유전자 변이로 발생된다. CPS1의 완전한 결핍을 가진 경우 신생아 시기에 빠르게 진행하는 고암모니아혈증으로 발현한다. 신생아 시기의 심한 고암모니아혈증은 즉각적인 치료를 받지 않을 시 심각한 뇌 손상, 혼수, 사망에 이르기에 진단 시 응급 투석과 체계적인 집중 치료가 필요하다. 본 증례는 생후 4일 째 신생아실에서 발열, 경련, 고암모니아혈증이 확인되어 생화학적, 분자유전학적 방법으로 두 개의 새로운 변이 c.1117G>C (p.Ala373 Pro)와 c.1883G>T (p.Gly628Val)가 이형접합체로 발견되고 CPS1 결핍이 진단된 신생아에서 응급 투석 및 집중치료와 함께 궁극적인 치료인 간이식 전 간세포이식술을 생후 1개월에 시행하여 반복적인 고암모니아혈증 발생을 막고 불가역적인 신경손상을 예방하여 현재 생후 6개월까지 단기간 경과관찰 결과 성장과 발달 및 신경학적 예후가 좋음을 보고하는 바이다. Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is an autosomal recessive disorder of the urea cycle that causes hyperammonemia. Two forms of CPS1D are recognized: a lethal neonatal type and a less severe, delayed-onset type. Neonatal CPS1D cases often present their symptoms within the first days of life. Delayed-onset cases are predominantly adolescents or adults, and infantile delayed-onset cases are rare. Severe hyperammonemia in the neonatal period leads to serious brain damage, coma, and death if not treated promptly. Therefore, early diagnosis and acute treatment are crucial. Despite the improvement of treatments, including continuous hemodialysis, ammonia-lowering agents, and a low-protein diet, the overall outcome of severe forms of hyperammonemia often remains disappointing. As the liver is the only organ in which ammonia is converted into urea, liver transplantation has been considered as an elegant and radical alternative therapy to classical dietary and medical therapies. However, liver transplantation has many disadvantages, such as a considerable risk for technical complications and perioperative metabolic derangement, especially in neonates. Additionally, there is a lack of suitable donor organs in most countries. According to recent studies, liver cell transplantation is a therapeutic option and serves as a bridge to liver transplantation. Here, we report a Korean CPS1D patient with novel mutations in CPS1 who was treated by liver cell transplantation after being diagnosed in the neonatal period and showed a good neurodevelopmental outcome at the last follow-up at six months of age.

새로운 유전자 돌연변이로 확진된 Ornithine Transcarbamylase (OTC) 결핍증 1례

송아리,이기욱,양아람,김진섭,박형두,조성윤,진동규,Song, Ari,Lee, Kiwuk,Yang, Aram,Kim, Jinsup,Park, Hyung-Doo,Cho, Sung Yoon,Jin, Dong-Kyu 대한유전성대사질환학회 2016 대한유전성대사질환학회지 Vol.16 No.3

요소 회로 대사 이상은 요소 합성에 관련된 효소의 결핍으로 인해 발생하는 질환으로, ornithine과 carbamylphosphate로부터 citrulline을 생성하는 과정에 관여하는 효소인 OTC 결핍증이 가장 흔하다. OTC 결핍증은 ammonia, glutamate, glutamine, alanine 등의 축적되면서 고암모니아 혈증 및 고글루타민 혈증으로 인한 신경학적 증상이 나타나게 되며, 근긴장 저하, 호흡 부전, 경련, 기면, 혼수로 진행하여 사망에 이르게 된다. 저자들은 생후 4일 경부터 구토와 함께 의식의 저하를 보인 환자에서 직열 질량 분석법을 통해 OTC 결핍증을 진단하였고, 증상 발생 31시간 만인 생후 118시간 째에 지속적 정정맥 혈액여과(continuous venovenous hemofiltration, CVVH)을 적용하여 고암모니아 혈증을 치료하였다. 또한 직접염기서열분석법을 통해 780번과 781번 염기 사이에 CAGGCAGTGT가 삽입되는 변이(c.780_781insCAGGCAGTGT (p.Ile261Glnfs*35))를 발견하였다. 환자는 4일 간의 CVVH 이후 혈중 암모니아 농도와 의식이 호전되어 생후 53일 째 퇴원하였으나, 생후 12개월 경 좌측 대퇴골의 골절과 골수염이 발생하였고, 이후 패혈증 쇼크, 고혈당, 다발성 장기부전으로 사망하였다. 이에 저자들은 OTC 결핍증 환자에서 CVVH 치료 및 패혈증과 당뇨를 경험하였고, 유전자 검사에서 이전에 보고된 바 없는 새로운 변이를 확인하였기에 증례를 보고하는 바이다. A urea cycle disorder is a condition caused by a defect of the enzymes in the urea cycle, and deficiency of ornithine transcarbamylase (OTC), which converts carbamoyl phosphate and ornithine into citrulline, is the most common type of the disorder. OTC deficiency induces the accumulation of precursors of urea, ammonia, and glutamine, leading to neurological symptoms including hypotonia, respiratory failure, seizure, lethargy, and coma and sometimes to death. Because OTC deficiency is inherited in an X-linked manner, typical symptoms such as vomiting, poor feeding, and lethargy appear mainly in male neonates. We recently had a case that presented with neonatal onset lethargy, vomiting, and apnea in a 4-day-old boy. He was diagnosed with OTC deficiency by biochemical phenotype, including hyperammonemia and an increased orotic acid level in the urine. Genetic analysis of the OTC gene showed a novel mutation c.780_781insCAGGCAGTGT (p.Ile261Glnfs*35). He was treated for hyperammonemia using continuous venovenous hemofiltration (CVVH) at 118 hours after birth. After 4 days of CVVH, his consciousness and blood ammonia concentration were normalized, and he was discharged at the age of 53 days. At around 12 months of age, bilateral femur fractures and osteomyelitis occurred in this patient. Two months after the fracture, he died of septic shock, insulin-resistant hyperglycemia, and multi-organ failure.

A Case of an 18-month-old Boy with Type 3 Gaucher Disease Presenting with Hepatosplenomegaly and Growth Retardation: The Clinical Course after Enzyme Replacement Therapy

임영신,황정윤,김진섭,양아람,박형두,전태연,조성윤,진동규,Lim, Young Shin,Hwang, Jeongyun,Kim, Jinsup,Yang, Aram,Park, Hyung Doo,Jeon, Tae Yeon,Cho, Sung Yoon,Jin, Dong-Kyu The Korean Society of Inherited Metabolic Disease 2017 대한유전성대사질환학회지 Vol.17 No.2

고셔병은 리소좀축적병으로 lysosomal hydrolase glucocerebrosidase 결여로 간비장비대, 골격계 증상, 빈혈, 혈소판 감소증의 증상을 나타내는 드문 상염색체 유전 질환이다. 본 증례에서는 18개월 남아에서 간비장비대, 성장 부진이 관찰되었으며 안구 운동 장애 및 발달 지연이 동반되어 제 3형 고셔병을 의심하였고 효소 분석 및 유전자 검사를 통해 확진하였다. 환아에서 한국인 신경형 고셔병에서 흔하게 관찰되는 c.754T>A(F213I)와 c.887G>A (R257Q)가 이형 접합체 돌연변이로 확인되었고 17개월 간의 효소 대체 요법을 통해 성장, 혈액학적 지표, 간비장비대 및 골증상은 호전되었지만 신경학적 증상의 호전은 없었고, 샤프론 중암브록솔에 유의한 반응이 있다고 알려져 있는 c.754T>A이 확인됨에 따라 환아에서 3개월간 암브록솔 치료를 시도하였지만 뚜렷한 임상적 치료 효과를 확인할 수 없었기에 본 증례를 보고하는 바이다. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by beta-glucosidase deficiency. An 18 month-old male with hepatosplenomegaly, anemia, thrombocytopenia, and growth retardation referred to our hospital. The patient showed neurological symptoms, such as supranuclear gaze palsy and developmental delay. Bone marrow biopsy performed to rule out malignancy and the results revealed no malignant cell; however, abnormal histiocytes suggesting storage disease was noted. Based on hepatosplenomegaly, bicytopenia and unexplained neurologic manifestations, enzyme activity and genetic analysis were conducted emergently with a strong suspicion of GD. Beta-glucosidase activity in leukocyte was decreased. GBA sequencing to confirm the diagnosis revealed compound heterozygous pathogenic variants (i.e., c.754T>A, c.887G>A), both previously reported as the cause of neuronopathic GD. Under the diagnosis of type 3 GD, the patient immediately received enzyme replacement therapy (ERT). After 17 months of ERT, the size of spleen decreased, and hemoglobin and platelet count returned to normal. In addition, the activity of chitotriosidase and angiotensin converting enzyme decreased. However, myoclonic movement and generalized seizure occurred at the age of 19 months and antiepileptic drug was started. Other neurological deterioration including supranuclear gaze palsy and developmental delay also persisted. A new therapy to overcome neurologic problems should be developed for patients with type 3 GD.

새로운 GNPTAB 유전자 돌연변이로 진단된 뮤코지방증 2형 1례를 포함한 국내 뮤코지방증 환자의 임상적 특징에 대한 분석

김진섭,양미선,양아람,조은혜,박형두,손영배,조성윤,진동규,Kim, Jinsup,Yang, Misun,Yang, Aram,Cho, Eun Hye,Park, Hyung-Doo,Sohn, Young Bae,Cho, Sung Yoon,Jin, Dong-Kyu 대한유전성대사질환학회 2017 대한유전성대사질환학회지 Vol.17 No.3

뮤코지방증 2형과 3형은 GlcNAc-1-phosphotransferase 효소의 기능 이상으로 인해 발생하는 상염색체 열성 유전질환이다. GlcNAc-1-phosphotransferase 효소의 기능 이상은 리소좀 효소의 세포 내 이동에 관여하는mannose-6-phosphate와 리소좀 효소간의 결합을 저해하여 리소좀 효소들이 세포 안으로 들어오지 못하게 된다. 리소좀 효소의 부족으로 인해 리소좀 기능 이상 및 뮤코지질의 축적으로 인해 다양한 임상을 보이게 된다. 본 연구는 새롭게 진단된 뮤코지방증 환자의 임상 및 생화학, 분자유전학적 양상을 기술하고 본원에서 치료받은 11명의 뮤코지방증 2, 3형 환자들의 임상 양상을 비교하여 분석하였다. 본 저자들은 17개월에 특징적 얼굴 모양 및 관절 구축을 주소로 내원한 환자에서 효소 검사를 통해 리조솜 효소의 혈장 내 증가를 확인하였으며 GNPTAB 유전자의 직접염기 서열분석을 통해 복합이형접합자 돌연변이 (c.3428 dupA [pAsn1143Lysfs*3], c.673C>T [p.Gln225*])를 발견하였다. 새로 진단된 환자를 포함하여 총 11명의 환자(뮤코지방증 2형: 7명, 3형: 4명)들을 대상으로 임상 양상을 분석하였고 진단 시 나이는 뮤코지방증 2형은 2세 1개월, 3형은 6세 9개월이었으며 진단 시 신장 표준편차지수는 각각 -3.2 (${\pm}1.5$), -1.3 (${\pm}1.1$)였다. 심초음파 결과에서 뮤코지방증 3형 환자들은 심장 판막의 이상만을 보였으나 2형 환자들에서는 비후성 심근증(n=3), 좌심비대(n=1)이 동반되었다. 간비비대(n=4)는 뮤코지방증 2형 환자에서만 확인되었다. 뮤코지방증 2형의 경우, 3명의 환자가 호흡 곤란으로 기관 절개 및 호흡기 보조를 받았으며 2 명의 환자가 호흡기 문제로 사망하였다. Pamidronate 치료는 4명의 뮤코지방증 3형 환자와 4명의 2형 환자에서 시행하고 있으며 유효성 및 안정성에 대한 추가적인 평가가 필요하다. Purpose: The aim of this study was to describe the clinical and biochemical features as well as the molecular analysis of a newly diagnosed illustrative case with ML II and to analyze the clinical features of 11 Korean patients with ML II/III. Method: Including a newly diagnosed patient, total 11 patients in 10 families were diagnosed as ML II (n=7) or ML III (n=4) were enrolled in the study. A diagnosis of ML II or III was made by demonstrating increased lysosomal enzyme activities in the plasma and sequence analysis of GNPTAB with characteristic clinical features. Result: A illustrative case of ML II patient was a 17 month-old boy showing characteristic facial appearance, multiple joint contractures with cardiac involvements. The enzyme assay showed increased lysosomal enzyme activities in the plasma. We identified compound heterozygous mutations in GNPTAB sequence analysis, including a frameshift (c.3428dupA [pAsn1143Lysfs*3]) and a nonsense variant c.673C>T (p.Gln225*). In total 11 patients with ML II/III, the patients with ML II showed severe growth retardation (height standard deviation score -3.2 [${\pm}1.5$]), compare to patients with ML III. Furthermore, patients with ML II patients had serious cardiac problem (n=4), hepatomegaly (n=3) and underwent tracheostomy (n=3) with further respiratory support due to respiratory distress. To improve osteoporosis and bone pain, all patients with ML III and four of 7 patients with ML II treated with intravenous pamidronate. Conclusion: Here we showed a newly diagnosed case of ML II and clinical features of 11 Korean patients with ML II or III. These data could be helpful for further diagnosis of mucolipidosis, a rare inherited metabolic disease, in Korea.

GNPTAB 유전자에서 새로운 돌연변이가 확인된 뮤코지방증 III형 남매

김민선,박에스더,송아리,임민지,박형두,조성윤,진동규,Kim, Min-Sun,Park, Esther,Song, Ari,Im, Minji,Park, Hyung-Doo,Cho, Sung Yoon,Jin, Dong-Kyu 대한유전성대사질환학회 2018 대한유전성대사질환학회지 Vol.18 No.3

뮤코지방증 III alpha/beta는 GNPTAB 유전자의 돌연변이로 야기되는 점액(Mucolipids) 분해 능력 장애이며 상염색체 열성으로 유전된다. 이는 혈액에서 고농축의 점액을 검사하여 진단되며 유전자 검사를 통해 진단을 확인할 수 있다. 뮤코지방증 III형은 희귀하고 점진적으로 진행하는 대사장애로 증상은 3세 경에 나타나며 성장지연, 관절 경직, 관절통, 골격 이상, 심장 판막 이상, 반복되는 호흡기 감염, 평평한 얼굴과 낮은 콧대의 거친 얼굴, 지적장애 또는 학습 문제를 보인다. 본 증례는 성장 지연과 거친 얼굴을 보이는 4세, 2세 7개월 남매에서 targeted gene panel sequencing으로 [c.2715+1G>A (p.Glu906Leufs*4), c.2544del (p. Glu849Lysfs*22)] 두 개의 변이가 이형 접합체로 발견되어 뮤코지방증 III형을 진단하였으며 c.2544del 은 새로운 돌연변이로 대조군에서 발견되지 않았고 표현형과 연관성 고려 시 pathogenic variant로 해석된다. 이와 같이 GNPTAB 유전자에서 새로운 돌연변이가 확인되어 뮤코지방증 III형 남매 증례를 보고하는 바이다. 본 증례처럼 최근 분자유전학적 기술이 발달함에 따라 조기 진단이 가능해지고 진단 후 Case 1 환자에서와 같이 치료를 위하여 pamidronate 투약 가능하나, 이와 같은 보조적 치료 외에도 조기 진단을 받은 뮤코지방증 환자들을 위한 근본적인 치료법 개발을 위한 노력이 필요하다. Mucolipidosis type III (pseudo-Hurler polydystrophy) is a mucolipids degrading disorder caused by a mutation in the GNPTAB gene and is inherited by autosomal recessive. It is diagnosed by examining highly concentrated mucolipids in blood and the diagnosis can be confirmed by genetic testing. Mucolipidosis type III is a rare and progressive metabolic disorder. Its initial signs and symptoms usually occur around 3 years of age. Clinical manifestations of the disease include slow growth, joint stiffness, arthralgia, skeletal abnormalities, heart valve abnormalities, recurrent respiratory infection, distinctive facial features, and mild intellectual disability. Here, we are presenting two siblings of mucolipidosis type III, a 4-year-old female and a 2 years and 7 months old male with features of delayed growth and coarse face. The diagnosis was confirmed by [c.2715+1G>A(p.Glu906Leufs*4), c.2544del(p.Glu849Lysfs*22)] mutation in targeted gene panel sequencing. In this case, c.2544del is a heterozygote newly identified mutation in mucolipidosis type III and was not found in the control group including the genome aggregation database. And it is interpreted as a pathogenic variant considering the association with phenotype. Here, we report a Korean mucolipidosis type III patients with novel mutations in GNPTAB gene who have been treated since early childhood. Owing to recent development of molecular genetic techniques, it was possible to make early diagnosis and treatment with pamidronate was initiated appropriately in case 1. In addition to these supportive therapies, efforts must be made to develop fundamental treatment for patients with early diagnosis of mucolipidosis.

경한 임상 경과를 보인 신생아 시기의 프로피온산혈증 1례

김경란,김진섭,허림,박형두,조성윤,진동규,Kim, Kyung-Ran,Kim, Jinsup,Huh, Rim,Park, Hyung-Doo,Cho, Sung Yoon,Jin, Dong-Kyu 대한유전성대사질환학회 2016 대한유전성대사질환학회지 Vol.16 No.1

프로피온산혈증은 상염색체 열성유전에 의해 발생하는 질환으로, 혈중에 암모니아, 독성 물질 등이 축적되어 경한 증상에서부터 사망에까지 이르는 질환이다. 유병률은 50,000-100,000명당 1명이다. PCCA 또는 PCCB 유전자의 돌연변이로 발생하며, 이것을 규명하는 것이 가장 확실한 진단 방법이다. 두 유형에 따른 임상경과 차이는 뚜렷하게 밝혀져 있지 않다. 발병 시기에 따라 신생아기형과 후기형으로 나눌 수 있다. 증상 발현의 원인은 이화작용을 강화시키는 감염, 스트레스, 변비, 단백질의 과도한 섭취 등이며, 운동실조, 이상행동, 식욕부진, 주기적 구토, 성장장애, 신경발달이상 등의 광범위한 임상 경과를 보인다. 정확한 진단과 조속한 초기 치료가 환자의 생존율 및 신경 발달 장애 여부에 중요한 요소이다. 본 증례는 고암모니아혈증 및 대사산증이 심하지 않았으나 조기에 대사성 질환을 염두에 두고 PCCA와 PCCB 유전자의 돌연변이를 분석하여 프로피온산혈증을 진단하고 적극적인 금식 및 수액 치료와 진단을 통해 신체 발달 및 운동 및 치명적인 신경학적 장애 없이 성장한 고무적인 사례로 이를 보고하는 바이다. Propionic acidemia (PA) is an autosomal recessively inherited disorder of the organic acid metabolism. It is caused by a deficiency of propionyl-CoA carboxylase (PCC). PCC is a heteropolymeric enzyme composed of ${\alpha}$- and ${\beta}$-subunits. The clinical symptoms of PA are heterogeneous and present vomiting, dehydration, hypotonia, and lethargy, and it can result in death. The typical presentations of neonatal onset PA are life-threatening metabolic acidosis and hyperammonemia. Here, we described a case of neonatal onset PA with mild clinical presentations. She was born to a healthy mother without complications. No significant illness was observed until nine days after birth. She started exhibiting poor oral feeding, vomiting, lethargy, and hypotonia at ten days old. Her laboratory results showed mild hyperammonemia and acidosis. The initial diagnosis was neonatal sepsis and she was treated with antibiotics. However, her clinical symptoms didn't improve. So we considered a metabolic disease. She was given nothing by mouth and intravenous hydration and nutrition support was performed. Propionylglycine and 3-hydroxypropionic acid were showed high concentrations in urine by gas chromatograph mass spectrometry (GC-MS). C3 level of acylcarnitine analysis elevated 10.4 uM/L (range, 0.200-5.00) in plasma. We took gene analysis for PA to be based on the symptoms and laboratory results. We detected PCCB gene mutation and diagnosed PA. She survived without severe neurologic defects and complications and was hospitalized only three times with upper respiratory tract infections for 7 years. We report a case of a ten days old neonate with PA presenting without severe metabolic acidosis and hyperammonemia who was effectively treated with early aggressive care and conventional methods.